What's Happening?
Eli Lilly and Company is actively recruiting a Senior Director, Market Access for its Lilly Regenerative Medicine (LRM) division. This role is pivotal in shaping the global market access strategy for LRM's gene therapy portfolio, which includes treatments
for ultra-rare diseases and common conditions like wet age-related macular degeneration (wet AMD). The Senior Director will be responsible for establishing a unified global pricing, access, and contracting framework for LRM assets, working in close collaboration with Lilly Value & Access (LV&A) in the U.S. and International Value & Access (IVA) teams. A key aspect of the position involves pioneering new payment models, such as durability-linked and outcomes-based contracts for one-time curative gene therapies, and building Lilly's first standardized playbook for these innovative approaches. The role also entails translating evidence into a strategic value proposition narrative for global value dossiers and representing LRM externally to influence policy and payer precedents for cell and gene therapies. The position requires a Bachelor's degree and over 10 years of progressive experience in market access, pricing, or payer strategy within the biopharma sector, with a strong emphasis on global or multi-country strategy ownership.
Why It's Important?
This strategic hire by Eli Lilly and Company underscores the growing importance of market access and pricing strategies in the rapidly evolving field of regenerative medicine, particularly for gene therapies. The development of novel payment models, such as outcomes-based contracts, is crucial for ensuring patient access to these potentially curative but high-cost treatments. By establishing a global framework, Lilly aims to streamline the commercialization process for its gene therapy portfolio, which could significantly impact the availability and affordability of these advanced medicines worldwide. The role's focus on influencing policy and payer precedents highlights the need for pharmaceutical companies to actively engage with regulatory bodies and healthcare systems to shape the future landscape of gene therapy reimbursement. Success in this area could set industry standards for how innovative therapies are valued and paid for, potentially benefiting patients by accelerating access to life-changing treatments and ensuring sustainable market entry for these complex products. The emphasis on building a net-new market access capability also signals a proactive approach to addressing the unique challenges posed by regenerative medicines.
What's Next?
The successful candidate for the Senior Director, Market Access position will immediately begin developing and implementing a global pricing and access framework for Lilly Regenerative Medicine's gene therapy assets. This will involve close coordination with internal teams like LV&A and IVA to customize strategies for various markets while maintaining a consistent global approach. A primary task will be to build Lilly's first standardized playbook for durability-linked and outcomes-based contracts, which will require significant collaboration with payers and health systems to pilot and refine these novel payment models. The Senior Director will also be instrumental in shaping external policy and payer precedents for cell and gene therapies, working with Lilly's government affairs to ensure a unified position on gene-therapy-specific policy questions. This will likely involve engagement with industry groups and regulatory bodies to advocate for favorable reimbursement pathways. The ongoing development and launch readiness for wet AMD and other pipeline retina assets will be a continuous focus, requiring the integration of market insights into commercial strategy and messaging.
Beyond the Headlines
The creation of this senior market access role reflects a broader industry trend towards navigating the complex economic and ethical considerations surrounding gene therapies. These treatments, often offering one-time curative potential, present unique challenges for traditional pricing and reimbursement models. The emphasis on outcomes-based and durability-linked contracts signifies a shift towards value-based healthcare, where payment is tied to the actual clinical benefits and long-term efficacy of a treatment. This approach could mitigate financial risks for payers and ensure that the high costs of gene therapies are justified by their long-term impact on patient health and healthcare utilization. Furthermore, the role's focus on influencing policy and payer precedents highlights the ethical imperative to ensure equitable access to these transformative therapies, particularly for ultra-rare diseases where patient populations are small and treatment options are limited. The success of this strategy could not only benefit Lilly but also contribute to the development of sustainable models for bringing other advanced regenerative medicines to patients in need, fostering innovation while addressing concerns about affordability and access.
